CABALETTA BIO INC (CABA)
US12674W1099 - Common Stock
Cabaletta Bio to Participate in Upcoming Investor Conferences in December
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
– Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this weekend in...
Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
Commit To Purchase Cabaletta Bio At $2.50, Earn 27.4% Annualized Using Options
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
PHILADELPHIA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and...
Thursday Sector Leaders: Semiconductors, Biotechnology Stocks
Oversold Conditions For Cabaletta Bio (CABA)
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
PHILADELPHIA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and...
CABA Stock Earnings: Cabaletta Bio Misses EPS for Q2 2024
CABA stock results show that Cabaletta Bio missed analyst estimates for earnings per share the second quarter of 2024.
CABA Stock Earnings: Cabaletta Bio Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cabaletta Bio (NASDAQ:CABA) just reported results for the second quarter of 202...
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
– Nine patients enrolled as of August 5, 2024 across the RESET™ clinical development program, including four since EULAR in June, with 22 U.S. clinical...
Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
PHILADELPHIA, July 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and...
Relative Strength Alert For Cabaletta Bio
First Week of CABA February 2025 Options Trading
Noteworthy Friday Option Activity: NAVI, CABA, GRMN
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 – – CABA-201...
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
Relative Strength Alert For Cabaletta Bio
CABA Stock Earnings: Cabaletta Bio Misses EPS for Q1 2024
CABA stock results show that Cabaletta Bio missed analyst estimates for earnings per share the first quarter of 2024.
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
– No CRS or ICANS of any grade observed during the 28-day DLT observation window for either of the first patients dosed with CABA-201 in the...